drugset / Trial / NCT01110941
Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China
Phase 1/2
Completed
20 enrolled
Shen Lin
307 Hospital of PLA · collabBeijing Union Hosptial · collabHebei Provincial Cancer Hospital · collabTianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal cancer. The new regimen with Oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on colorectal cancer. This study is to explore the feasibility of the SOL regimen on efficacy and tolerability on Chinese colorectal cancer patients.
Timeline
- Start
- 2009-09
- Primary completion
- 2010-03
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | 25 mg | Oral |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 40 mg | Oral |
| Subject | S-1 | Small molecule | 60 mg | Oral |